HUMAN ANTI IL6R (TOCILIZUMAB BIOSIMILAR)

Human Anti-IL6R Antibody, clone rhPM-1 is a research grade biosimilar of the monoclonal antibody drug tocilizumab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic antibody tocilizumab. Human Anti-IL6R Antibody is for research use only. It is suitable as a reference standard in a pharmacokinetic (PK) bridging ELISA with anti-tocilizumab antibodies, for example HCA252 and HCA253P. It can also be used as capture and detection reagent in an anti-drug antibody (ADA) bridging ELISA, with an anti-tocilizumab antibody in IgG1 format as reference standard, for example HCA253. Tocilizumab (Actemra/RoActemra) is a humanized IgG1/kappa monoclonal antibody approved for the treatment of moderate to severe rheumatoid arthritis and for the treatment of systemic juvenile idiopathic arthritis. The therapeutic antibody is directed against IL-6R and acts by blocking the binding of IL-6R (both the soluble form, sIL-6R, and the membrane bound form, mIL-6R) to IL-6, thus impeding the pro-inflammatory properties of this cytokine. This product is NOT FOR THERAPEUTIC USE.View a summary of supporting anti-tocilizumab antibody products

• Clonality: Monoclonal
• Host: Human
• Reactivity: Human
• Isotype: IgG1

• Quantity: 0.2 mg
• Storage: +4ºC, -20ºC if preferred
• Buffer: Phosphate buffered saline, 0.02% Proclin 300

• ELISA (ELISA)